The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
In the age of Topo1 clinical saturation and threat of patient resistance mechanisms, the need for differentiation is not a new challenge for the ADC community. With biopharma investing heavily into de-risk future ADC development, non-traditional ADCs continue to take the spotlight to secure an effective future landscape of therapies to patients in need.
Across bispecific and dual payload ADCs, DACs, AOCs, ISACs and beyond, the 10-year CAGR of non-traditional ADC unique patent families published is 23% vs 11% for traditional ADCs. Between January 2025 to February 2026, the number of non-traditional ADC drugs almost doubled, with 99% growth and 575 non-traditional ADCs identified*.
The 17th World ADC San Diego held the standard to be at the forefront of bioconjugate development, spotlighting all the avenues of ADC innovation under one roof. Attendees joined World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.
*Data according to Beacon – correct as of April 2026.
Explore the Full 4-Day Experience
- 1,300+ Industry Attendees
- 400+ Attending Companies
- 170+ World-Class Speaker Faculty
- 7 Tracks of End-to-End ADC Content
- The World’s Largest & Definitive ADC Forum
Brand New Companies Who Made Their World ADC Debut
Included within the 170+ industry-leading speaker faculty, World ADC San Diego is committed to spotlight novel perspectives on ADC development, with brand-new presenting companies:
Explore the 2026 Agenda
Hear the latest industry insights and discover cutting-edge, end-to-end ADC content from early discovery to late-stage manufacturing.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.